Sepracor Seeks FDA Nod For Long-Acting Beta Agonist Arformoterol
This article was originally published in The Pink Sheet Daily
Executive Summary
User fee date for the chronic obstructive pulmonary disease agent would fall in October, assuming a standard 10-month review.
You may also be interested in...
Sepracor COPD Treatment Approved
Brovana will be first-to-market long-acting bronchodilator developed in an inhalation solution for use with a nebulizer.
Sepracor COPD Treatment Approved
Brovana will be first-to-market long-acting bronchodilator developed in an inhalation solution for use with a nebulizer.
Sepracor Will Support Xopenex HFA Launch With Three Sales Forces
The firm will use two primary care sales forces and one specialty respiratory sales force to detail the hydrofluoroalkane metered-dose inhaler.